Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cubist Pharmaceuticals, a biopharmaceutical company, has announced that the company has submitted two investigational new drug applications with the FDA on December 23, 2008 for an antibiotic drug.
Subscribe to our email newsletter
The investigational new drug applications (INDs) signify the company’s intentions to begin clinical investigation for CB-182,804, a Cubist-discovered, potent, cidal, IV lipopeptide in development as therapy for the treatment of multi-drug resistant gram-negative infections, and CB-183,315, a Cubist-discovered, potent, oral, cidal lipopeptide in development for the treatment of Clostridium difficile associated diarrhea.
Mike Bonney, president and CEO of Cubist, said, “These INDs demonstrate our continued commitment to building a significant product pipeline in the acute care setting. I am particularly proud that both of these antibiotic candidates are based on discoveries by Cubist scientists.”